In the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) of IL-1 inhibition in patients with prior myocardial infarction, patients with more robust reductions in IL-6 had greater CV benefit from targeted anti-inflammatory therapy.31 This evidence concerns the gene IL6 and myocardial infarction.